cidofovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals phosphonic acid derivatives 639 113852-37-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cidofovir
  • cidofovir monophosphate
  • cidovir
  • vistide
  • sidofovir
  • cidofovir dihydrate
  • anhydrous cidofovir
  • cidofovir hydrate
An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.
  • Molecular weight: 279.19
  • Formula: C8H14N3O6P
  • CLOGP: -1.99
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 4
  • TPSA: 145.68
  • ALOGS: -1.38
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 170 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 90 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 17.91 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.49 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.60 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ULK1,ZAP70 52
kinase-selectivity-class AXL,BRAF,CDK4,CDK9,EPHB4,ERBB2,GRK2,IRAK3,MAP2K6,MAP3K14,MAPK7,PIK3CD,PRKDC,SYK,TEK,TGFBR1,ZAP70 17
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
June 26, 1996 FDA GILEAD SCIENCES INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Adenovirus infection 220.95 73.60 44 2076 4578 90621749
Viral haemorrhagic cystitis 186.53 73.60 32 2088 1461 90624866
Drug resistance 176.77 73.60 53 2067 30396 90595931
Cytomegalovirus infection reactivation 108.27 73.60 27 2093 7773 90618554
Nephropathy toxic 104.37 73.60 29 2091 12659 90613668
Hypouricaemia 94.22 73.60 14 2106 250 90626077
Cystitis haemorrhagic 91.31 73.60 22 2098 5491 90620836
BK virus infection 90.43 73.60 21 2099 4477 90621850
Acidosis hyperchloraemic 83.51 73.60 15 2105 891 90625436
Off label use 81.60 73.60 113 2007 1102139 89524188
Immune reconstitution inflammatory syndrome 76.31 73.60 20 2100 6999 90619328
Epstein-Barr virus infection reactivation 74.65 73.60 15 2105 1622 90624705

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 163.06 46.15 60 1829 34188 42585258
Cystitis haemorrhagic 134.15 46.15 36 1853 7293 42612153
Off label use 110.64 46.15 137 1752 638198 41981248
Adenovirus infection 99.35 46.15 28 1861 6781 42612665
Drug ineffective 80.69 46.15 117 1772 630080 41989366
Drug ineffective for unapproved indication 72.49 46.15 37 1852 46126 42573320
Pathogen resistance 54.09 46.15 20 1869 11430 42608016
Nephropathy toxic 53.31 46.15 22 1867 16816 42602630
JC virus infection 51.36 46.15 14 1875 2990 42616456
Cytomegalovirus infection 50.97 46.15 26 1863 32280 42587166
Cytomegalovirus viraemia 48.55 46.15 18 1871 10359 42609087

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 336.16 54.57 111 3891 56263 110529034
Adenovirus infection 267.17 54.57 65 3937 10929 110574368
Cystitis haemorrhagic 215.99 54.57 56 3946 12153 110573144
Off label use 178.52 54.57 242 3760 1499943 109085354
Nephropathy toxic 155.08 54.57 52 3950 27426 110557871
Viral haemorrhagic cystitis 151.80 54.57 33 3969 3366 110581931
Drug ineffective 146.27 54.57 222 3780 1520318 109064979
Cytomegalovirus infection reactivation 141.46 54.57 44 3958 18289 110567008
Pathogen resistance 138.82 54.57 43 3959 17629 110567668
BK virus infection 138.06 54.57 40 3962 13066 110572231
Cytomegalovirus infection 117.21 54.57 51 3951 54393 110530904
Epstein-Barr virus infection reactivation 113.85 54.57 27 3975 4057 110581240
Immune reconstitution inflammatory syndrome 108.81 54.57 35 3967 16191 110569106
Renal impairment 105.05 54.57 72 3930 188373 110396924
Cytomegalovirus viraemia 93.81 54.57 32 3970 17732 110567565
Acute kidney injury 82.97 54.57 108 3894 635322 109949975
Hypouricaemia 77.13 54.57 14 3988 564 110584733
Drug ineffective for unapproved indication 76.15 54.57 47 3955 102791 110482506
Polyomavirus-associated nephropathy 73.08 54.57 22 3980 8179 110577118
Acidosis hyperchloraemic 68.57 54.57 15 3987 1571 110583726
Herpes simplex 62.66 54.57 23 3979 15741 110569556
Bladder hypertrophy 62.03 54.57 13 3989 1111 110584186
Renal tubular injury 58.54 54.57 15 3987 3093 110582204
Polyomavirus viraemia 56.88 54.57 15 3987 3459 110581838
Human herpesvirus 6 infection 55.83 54.57 17 3985 6564 110578733
Multiple organ dysfunction syndrome 55.35 54.57 45 3957 151665 110433632
Acute graft versus host disease in skin 55.33 54.57 19 3983 10721 110574576
Adenovirus reactivation 55.24 54.57 11 3991 729 110584568
JC virus infection 55.04 54.57 16 3986 5274 110580023

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AB12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 11 drugs
acyclovirbrivudinefamciclovirgancicloviridoxuridinemolnupiravirpenciclovirremdesivirvalaciclovirvalganciclovirvidarabine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
CMV Retinitis in AIDS Patients indication
Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients indication
Prevention of Cytomegalovirus Disease off-label use
Acidosis contraindication 51387008
Kidney disease contraindication 90708001 DOID:557
Severe Chronic Neutropenia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.81 acidic
pKa2 12.99 acidic
pKa3 4.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
DNA polymerase catalytic subunit Enzyme INHIBITOR WOMBAT-PK CHEMBL

External reference:

IDSource
4020976 VUID
N0000148447 NUI
D00273 KEGG_DRUG
83170 RXNORM
C0286079 UMLSCUI
CHEBI:3696 CHEBI
L8P PDB_CHEM_ID
CHEMBL5314375 ChEMBL_ID
DB00369 DRUGBANK_ID
D000077404 MESH_DESCRIPTOR_UI
60613 PUBCHEM_CID
JIL713Q00N UNII
194597 MMSL
4446 MMSL
6016 MMSL
d04028 MMSL
006053 NDDF
108688007 SNOMEDCT_US
278161000202101 SNOMEDCT_US
386894007 SNOMEDCT_US
CHEMBL152 ChEMBL_ID
149394-66-1 SECONDARY_CAS_RN
4020976 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CIDOFOVIR DIHYDRATE HUMAN PRESCRIPTION DRUG LABEL 1 23155-216 INJECTION, SOLUTION 375 mg INTRAVENOUS ANDA 21 sections
Vistide HUMAN PRESCRIPTION DRUG LABEL 1 61958-0101 INJECTION 75 mg INTRAVENOUS NDA 24 sections
CIDOFOVIR HUMAN PRESCRIPTION DRUG LABEL 1 67457-210 INJECTION, SOLUTION 75 mg INTRAVENOUS ANDA 26 sections